Radio Advisory

The episode delivers solid technical and strategic insights into Medicare Advantage payment mechanics, risk adjustment models, and implications for payers and providers. However, it stays largely within expected expert analysis territory - breaking down the 2.5% rate increase, explaining risk adjustment changes, and discussing portfolio strategy. While substantive, the insights are more confirmatory than revelatory; a healthcare operator familiar with MA would recognize most of these concerns and trade-offs.

“The key change that was made in the MA rate announcement was that the risk adjustment model changes weren't as bad as what they had proposed in the advance notice, and that was the big concern that I think the stock market and payers were concerned about”

“If my revenue is only going up by 2.5%, well, I certainly can't afford to pay my providers an extra 3% that they're asking for”

The episode applies standard actuarial frameworks and known policy levers (rate increases, risk adjustment, Stars programs, benefit restrictions) without introducing genuinely novel perspectives or counterintuitive arguments. The framing of MA as a system in contraction vs. prior growth is important but not particularly fresh. The guest doesn't challenge conventional wisdom or propose non-obvious solutions.

“Most recently, trends were focused on C-SNPs and the whole SNP market in terms of where we can acquire membership”

“Consolidation is a reality here in the near term”

Alex Balmes brings 23 years of actuarial consulting experience specifically in government payment spaces, 8 years in R&D for actuarial modeling, and current VP-level position at Optum, a major payer. He demonstrates genuine technical depth (understanding V28 model coefficients, linked/unlinked chart review mechanics, bid forecasting complexity) and strategic perspective from operating inside the ecosystem. This is a credible, well-positioned operator rather than a career commentator.

“Alex has been doing actuarial consulting for payers and providers in the government payment space for 23 years, including eight years in R&D for actuarial models”

“VP of actuarial services for Optum”

The episode grounds discussion in concrete figures: 2.5% aggregate rate increase, 10-20% stock drops on advance notice, 5-10% rebound on final notice, out-of-pocket maximum increase from $2,100 to $2,400, 35 million MA enrollees. Named entities include Optum, CMS, PBMs, and specific policy mechanisms (V28 model, RxHCC, linked/unlinked charts, C-SNPs). However, lacks company-level case studies, named examples of provider/payer struggles, or specific cost trend data that would elevate specificity further.

“about a 2.5% increase in overall MA reimbursement”

“stocks of major health insurance companies who operate Medicare Advantage plans dropped as much as 10 to 20% in a single day”

Abby Burns asks clear, well-structured questions that move logically from overview (what CMS did) to implications (what payers and providers should do) to longer-term strategy. However, she rarely presses back or challenges the guest; when Balmes makes broad claims (e.g., 'the government plays a critical role'), she affirms rather than probe. Follow-ups are mostly invitations to expand on announced topics rather than sharp interrogation of assumptions or tensions in his argument.

“Why is it important that health system leaders understand the technical components that go into that final 2.48% growth?”

“I want to ask a similar question on the plan side to what we talked about on the provider side, which is around drug spend”